|
|
Post by dreamboatcruise on Jun 5, 2018 16:07:38 GMT -5
United Therapeutics bought Steadymed Ltd. for $216M. They have a TREVYENT (Dev. Stage) which is a Patch/Pump Device for PAH. United Therapeutics To Acquire SteadyMed Ltd. SILVER SPRING, Md. and SAN RAMON, Calif., April 30, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) and SteadyMed Ltd. (NASDAQ: STDY) announced today the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and an additional $2.63 per share in cash upon the achievement of a milestone related to the commercialization of Trevyent®. The transaction, including the $75 million in contingent consideration, is valued at $216 million. SteadyMed is a specialty pharmaceutical company focused on the development and commercialization of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs. SteadyMed's product portfolio includes Trevyent, a development-stage drug-device combination product that combines SteadyMed's two day, single use, disposable PatchPump® technology with treprostinil, a vasodilatory prostacyclin analogue, for the subcutaneous treatment of pulmonary arterial hypertension (PAH). United Therapeutics is a leading biotechnology company focused on the development and commercialization of therapies for the treatment of PAH and other orphan diseases. "We are optimistic about acquiring SteadyMed and adding Trevyent to our pipeline of products to treat PAH," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. "We are especially impressed with SteadyMed's management team and global supply chain. Trevyent fits in well with our mission, and we look forward to bringing the product to the maximum number of patients as soon as possible." "United Therapeutics has always been at the forefront of developing therapies to treat PAH, and we are delighted at the prospect of our companies coming together, as one, to continue that mission," said Jonathan M.N. Rigby, President and Chief Executive Officer of SteadyMed. "We believe that this proposed acquisition will help us realize our commitment to bring Trevyent to market to improve the lives of patients with PAH." According to Steadymed PR they believe it will be approved by end of this year. It is cumbersome having a pump attached, but a steady infusion might provide better results than periodic dry powder dosing ? ? I would assume (and backed by medical professional surveys cited by Steadymed) that this pump system will gain market share rapidly from the other available treatments such as the nebulizer. So by the time TreT hits the market that may be the SOC... or on its way. |
|
|
|
Post by goyocafe on Jun 5, 2018 16:18:09 GMT -5
United Therapeutics bought Steadymed Ltd. for $216M. They have a TREVYENT (Dev. Stage) which is a Patch/Pump Device for PAH. United Therapeutics To Acquire SteadyMed Ltd. SILVER SPRING, Md. and SAN RAMON, Calif., April 30, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) and SteadyMed Ltd. (NASDAQ: STDY) announced today the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and an additional $2.63 per share in cash upon the achievement of a milestone related to the commercialization of Trevyent®. The transaction, including the $75 million in contingent consideration, is valued at $216 million. SteadyMed is a specialty pharmaceutical company focused on the development and commercialization of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs. SteadyMed's product portfolio includes Trevyent, a development-stage drug-device combination product that combines SteadyMed's two day, single use, disposable PatchPump® technology with treprostinil, a vasodilatory prostacyclin analogue, for the subcutaneous treatment of pulmonary arterial hypertension (PAH). United Therapeutics is a leading biotechnology company focused on the development and commercialization of therapies for the treatment of PAH and other orphan diseases. "We are optimistic about acquiring SteadyMed and adding Trevyent to our pipeline of products to treat PAH," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. "We are especially impressed with SteadyMed's management team and global supply chain. Trevyent fits in well with our mission, and we look forward to bringing the product to the maximum number of patients as soon as possible." "United Therapeutics has always been at the forefront of developing therapies to treat PAH, and we are delighted at the prospect of our companies coming together, as one, to continue that mission," said Jonathan M.N. Rigby, President and Chief Executive Officer of SteadyMed. "We believe that this proposed acquisition will help us realize our commitment to bring Trevyent to market to improve the lives of patients with PAH." According to Steadymed PR they believe it will be approved by end of this year. It is cumbersome having a pump attached, but a steady infusion might provide better results than periodic dry powder dosing ? ? I would assume (and backed by medical professional surveys cited by Steadymed) that this pump system will gain market share rapidly from the other available treatments such as the nebulizer. So by the time TreT hits the market that may be the SOC... or on its way. ...believe...might...assume...may... Other than those words burried in this paragraph, it seems quite factual. 🙃 |
|
|
|
Post by dreamboatcruise on Jun 5, 2018 16:25:10 GMT -5
According to Steadymed PR they believe it will be approved by end of this year. It is cumbersome having a pump attached, but a steady infusion might provide better results than periodic dry powder dosing ? ? I would assume (and backed by medical professional surveys cited by Steadymed) that this pump system will gain market share rapidly from the other available treatments such as the nebulizer. So by the time TreT hits the market that may be the SOC... or on its way. ...believe...might...assume...may... Other than those words burried in this paragraph, it seems quite factual. 🙃 I think it less factual without those words. Adding in those words in fact makes it more factual. I too often see people here stating speculation as fact without stating that it is someone's belief or expectation rather than a certainty. Though I also gather that some here simply think things should always be stated as certainties or not discussed at all... or state the good for MNKD with certainty and question anything less than good. In the case of Steadymed, according to the PR this is the plan agreed to by the FDA. So I'd at least put the certainty level on the same footing as MNKD's accelerated timeline that was based on its meetings with FDA. But yes, the "true long" way of looking at this would be to imply absolute certainty for MNKD's schedule and question the same for Steadymed. Based on MNKD and Steadymed, I wouldn't be surprised if Liquidia isn't trying to work out some sort of accelerated process with FDA. It seems FDA has taken a position that PAH is in dire need of new options and thus expediting the process for new Trep options. Perhaps there is a reason Liquidia should be treated differently, but it is curious. |
|
|
|
Post by uvula on Jun 7, 2018 8:31:32 GMT -5
This mornings press release (already mentioned in another thread) confirms that some folks here know what they're talking about.
|
|
